Skip to main content
CTOS 2024 Main banner
Final Program


Schedule at a Glance
Icon Legend
This session is not in your schedule.
This session is in your schedule. Click again to remove it.
Back

Session 11: Trials in Progress/Late Breaking Trials

Saturday, November 16, 2024
9:00 AM – 10:00 AM PST
Location: Harbor Ballroom

Presentations:

  • 9:00 AM – 10:00 AM PST
    SARCOSIGHT- A RANDOMISED CONTROLLED TRIAL OF FLUORESCENCE GUIDED SARCOMA SURGERY VERSUS STANDARD OF CARE

    Author: Kenneth Rankin, MBChB MD FRCS – North of England Bone and Soft Tissue Tumour Service

    Co-Author: Marcus Brookes, MBBS, MRes, MRCS, PGCert – The Newcastle upon Tyne Hospitals NHS Foundation Trust

    Co-Author: Corey D. Chan, MBBS MRes – Newcastle University Centre for Cancer

    Co-Author: Craig Gerrand, MD – Royal National Orthopaedic Hospital, NHS England

    Co-Author: Maniram Ragbir, FRCS – North of England Bone and Soft Tissue Tumour Service

    Co-Author: Alastair Burt, MD FRCPath – Newcastle University

  • 9:00 AM – 10:00 AM PST
    PREOPERATIVE VS POSTOPERATIVE INTENSITY MODULATED RADIATION THERAPY FOR TRUNCAL/EXTREMITY SOFT TISSUE SARCOMA

    Author: Anthony Griffin, MSc – Mount Sinai Hospital- Orthopaedics

    Co-Author: Charles Catton, MD – Princess Margaret Cancer Centre

    Co-Author: David Shultz, MD, PhD – Princess Margaret Cancer Centre, University Health Network

    Co-Author: Philip Wong, MD – Princess Margaret Cancer Centre

    Co-Author: David G. Kirsch, MD, PhD – Princess Margaret Cancer Centre

    Co-Author: Jay Wunder, MD, MSc, FRCSC – University of Toronto

    Co-Author: Kim Tsoi, MD, PhD – Division of Orthopedic Surgery, University Musculoskeletal Oncology Unit, Mount Sinai Hospital, Toronto, Ontario, Canada;; University of Toronto, Toronto, Canada

    Co-Author: Kenneth R. Gundle, MD – Oregon Health & Science University

    Co-Author: Arthur Hung, MD – Oregon Health & Science University

    Co-Author: Rebecca Smith, MA (she/her/hers) – Oregon Health & Science University

    Co-Author: Thomas Schubert, MD, PhD – Cliniques universitaires Saint-Luc

    Co-Author: Xavier Geets, MD – Cliniques universitaires Saint-Luc

    Co-Author: Sophie Mottard, Dr – CEMTL

    Co-Author: Georges Basile, MD – Hopital Maisonneuve-Rosemont

    Co-Author: Nader Khaouam, MD – Hopital Maisonneuve-Rosemont

    Co-Author: Janie Barry, M.Sc – CEMTL

    Co-Author: Hugo Saint-Yves, M.Sc (he/him/his) – CEMTL

    Co-Author: Lukas Nystrom, MD – Cleveland Clinic

    Co-Author: Nathan Mesko, MD – Cleveland Clinic

    Co-Author: Chirag Shah, MD – Cleveland Clinic

    Co-Author: Elizabeth Baldini, MD – Dana-Farber Cancer Institute

    Co-Author: Peter Ferguson, MD, MSc, FRCSC – University of Toronto

    Co-Author: Peter Chung, MD – Princess Margaret Cancer Centre

  • 9:00 AM – 10:00 AM PST
    A RANDOMIZED PHASE III TRIAL OF DOXORUBICIN + PEMBROLIZUMAB VERSUS DOXORUBICIN ALONE FOR TREATMENT OF UNDIFFERENTIATED PLEOMORPHIC SARCOMA AND RELATED POORLY DIFFERENTIATED SARCOMAS: ECOG-ACRIN EA7222

    Author: Seth M. Pollack, MD – Northwestern University, Feinberg School of Medicine, Department of Medicine, Division of Oncology, Chicago

    Co-Author: Opeyemi Jegede, PhD – Harvard

    Co-Author: Candace L. Haddox, MD – Dana Farber Cancer Institute

    Co-Author: Michael J. Wagner, MD – Dana-Farber Cancer Institute

    Co-Author: Ronnie Siebro, MD (he/him/his) – Mayo

    Co-Author: Richard F. Riedel, MD – Duke Cancer Institute

    Co-Author: Kenneth Cardona, MD – Winship Cancer Institute

  • 9:00 AM – 10:00 AM PST
    A MULTICENTER, RANDOMIZED, PHASE 3 STUDY OF INTRATUMORAL INT230-6 (SHAO, VINBLASTINE, CISPLATIN) COMPARED TO STANDARD OF CARE THERAPY IN SELECTED METASTATIC SOFT TISSUE SARCOMAS: INVINCIBLE-3 TRIAL.

    Author: Albiruni Abdul Razak, MB BCh, BAO, LRCP & SI – Toronto Sarcoma Program, Princess Margaret Cancer Center

    Presenter: Christian F. Meyer, MD PhD (he/him/his) – John Hopkins

    Co-Author: Lewis H. Bender, MS, MA, MBA (he/him/his) – Intensity Therapeutics

    Co-Author: Kimberly A. Guedes – Intensity Therapeutics

    Co-Author: Brian E. Schwartz, n/a – Intensity Therapeutics

  • 9:00 AM – 10:00 AM PST
    PHASE 3 STUDY OF IVOSIDENIB VS PLACEBO IN LOCALLY ADVANCED OR METASTATIC IDH1-MUTANT CONVENTIONAL CHONDROSARCOMA UNTREATED OR PREVIOUSLY TREATED WITH 1 SYSTEMIC TREATMENT REGIMEN (CHONQUER)

    Author: William D. Tap, MD – Department of Medicine, Memorial Sloan Kettering Cancer Center Department of Medicine, Weill Cornell Medical College

    Co-Author: Silvia Stacchiotti, MD – Fondazione IRCCS Istituto Nazionale dei Tumori

    Co-Author: Antoine Italiano, MD, PhD – Institut Bergonié

    Co-Author: Jonathan Trent, MD, PhD – Sylvester Comprehensive Cancer Center, University of Miami Health System

    Co-Author: Ilona Tala, PhD – Servier Bio-Innovation

    Co-Author: Zhe Qu, PhD – Servier Bio-Innovation

    Co-Author: Diego A. Gianolio, PhD (he/him/his) – Servier Bio-Innovation

    Co-Author: Channa Debruyne, MD – Servier R&D

    Co-Author: Jean-Yves Blay, MD, PhD – Centre Léon Bérard

    Co-Author: Andrew J. Wagner, MD, PhD – Dana-Farber Cancer Institute

  • 9:00 AM – 10:00 AM PST
    A PHASE 2/3 STUDY EVALUATING THE EFFICACY AND SAFETY OF UNESBULIN IN ADVANCED LEIOMYOSARCOMA (SUNRISELMS)

    Author: Brian A. Van Tine, MD, PhD – Washington University in St. Louis

    Co-Author: Jean-Yves Blay, MD, PhD – Centre Léon Bérard

    Co-Author: Gary K. Schwartz, MD – Case Comprehensive Cancer Center

    Co-Author: John D. Baird, N/A (he/him/his) – PTC Therapeutics, Inc.

    Co-Author: Dhiren D'Silva, N/A (he/him/his) – PTC Therapeutics, Inc.

    Co-Author: John Finnefrock, PharmD – PTC Therapeutics, Inc.

    Co-Author: Kylie O'Keefe, N/A – PTC Therapeutics, Inc.

    Co-Author: Mark Rance, N/A – PTC Therapeutics, Inc.

    Co-Author: Marla Weetall, N/A – PTC Therapeutics, Inc.

    Co-Author: Robin L. Jones, BSc, MB BS, MRCP, MD – Sarcoma Unit, The Royal Marsden NHS Foundation Trust and Institute of Cancer Research